Skip to content

Study · Case report or series · n = 16 · 2026

5 results

Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.

Wong K, Al-Amri H, Werlang A

Case reports in women's health18 Jun 2026

PMID42376629 (opens in a new tab)PMCIDPMC13310638 (opens in a new tab)DOI10.1016/j.crwh.2026.e00831 (opens in a new tab)PepBankPUB-42376629
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In 16 pregnancies with first-trimester semaglutide exposure, no major fetal anomalies were identified.

    In plain wordsIn 16 pregnancies where semaglutide was used early on, no major birth defects were found.

    Peptide
    Semaglutide
    Outcome
    No significant changeMajor fetal anomalies
    Study

    n = 16

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous · part of the first trimesterAs given in this study (human).

    Source sentences

    Summary
    No major fetal anomalies were identified.
    3 context sentences
    Summary · context
    All had spontaneous and unplanned conception of singleton pregnancies while using subcutaneous semaglutide and continued administration during a part of the first trimester.
    Summary · context
    This case series included individuals receiving obstetric care at a tertiary perinatal center who had exposure to a GLP-1 RA between 2 months preconception to pregnancy conclusion for any indication or duration.
    Summary · context
    There were 16 patients in the series.
  2. 02HumanCase report or seriesSafety outcome

    In 16 pregnancies with first-trimester semaglutide exposure, the rate of preeclampsia was 18.8%.

    In plain wordsIn 16 pregnancies where semaglutide was used early on, preeclampsia occurred in 18.8%.

    Peptide
    Semaglutide
    Outcome
    Not applicablePreeclampsia rate
    Study

    n = 16

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous · part of the first trimesterAs given in this study (human).

    Measurements

    Preeclampsia rate
    18.8%
    case series

    Source sentences

    Summary
    The rate of preeclampsia was 18.8%.
    2 context sentences
    Summary · context
    This case series included individuals receiving obstetric care at a tertiary perinatal center who had exposure to a GLP-1 RA between 2 months preconception to pregnancy conclusion for any indication or duration.
    Summary · context
    There were 16 patients in the series.
  3. 03HumanCase report or seriesSafety outcome

    In 16 pregnancies with first-trimester semaglutide exposure, there was one iatrogenic preterm birth at 35 weeks for preeclampsia.

    In plain wordsIn 16 pregnancies where semaglutide was used early on, one baby was born early at 35 weeks because of preeclampsia.

    Peptide
    Semaglutide
    Outcome
    Not applicableIatrogenic preterm birth
    Study

    n = 16

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous · part of the first trimesterAs given in this study (human).

    Measurements

    Gestational age at preterm birth
    35 weeks
    one case

    Source sentences

    Summary
    There was one instance of iatrogenic preterm birth at 35 weeks for preeclampsia.
    2 context sentences
    Summary · context
    This case series included individuals receiving obstetric care at a tertiary perinatal center who had exposure to a GLP-1 RA between 2 months preconception to pregnancy conclusion for any indication or duration.
    Summary · context
    There were 16 patients in the series.
  4. 04HumanCase report or seriesEfficacy outcome

    In 16 pregnancies with first-trimester semaglutide exposure, excessive gestational weight gain (37.5%) was lower than expected given the high rate of obesity.

    In plain wordsIn 16 pregnancies where semaglutide was used early on, 37.5% gained too much weight, less than expected for people with obesity.

    Peptide
    Semaglutide
    Outcome
    Not applicableExcessive gestational weight gain
    Study

    n = 16

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · part of the first trimesterAs given in this study (human).

    Measurements

    Excessive gestational weight gain
    37.5%
    case series

    Source sentences

    Summary
    Given the high rate of obesity, there was a lower-than-expected rate of excessive gestational weight gain (37.5%).
    2 context sentences
    Summary · context
    This case series included individuals receiving obstetric care at a tertiary perinatal center who had exposure to a GLP-1 RA between 2 months preconception to pregnancy conclusion for any indication or duration.
    Summary · context
    There were 16 patients in the series.
  5. 05HumanCase report or seriesEfficacy outcome

    In 16 overweight or obese pregnancies with first-trimester semaglutide exposure, no individual lost weight in pregnancy.

    In plain wordsIn 16 pregnancies where semaglutide was used early on, nobody lost weight during pregnancy.

    Peptide
    Semaglutide
    Outcome
    Not applicableWeight loss in pregnancy
    Study

    n = 16

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · part of the first trimesterAs given in this study (human).

    Source sentences

    Summary
    No individual lost weight in pregnancy.
    3 context sentences
    Summary · context
    All included patients were overweight or obese.
    Summary · context
    This case series included individuals receiving obstetric care at a tertiary perinatal center who had exposure to a GLP-1 RA between 2 months preconception to pregnancy conclusion for any indication or duration.
    Summary · context
    There were 16 patients in the series.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.